Are You Being Served? | GenomeWeb

Are You Being Served?

Premium

As you’ll read in this issue, midsize sequencing facilities are trying to figure out how to keep themselves relevant, and Amersham Biosciences is trying to figure out how to keep its customers happy. New NHGRI funding policies and current biopharma spending patterns have served to heighten the need for re-examining goals, but in an industry that’s evolving and changing as quickly as this one, organizations need to stay in a constant state of self-scrutiny just to keep up. Genome Technology is no exception.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.